title: Effect of chronic duodenal ulceration and its treatment with lanzoprazole or sucralfate on gastroduodenal mucosal protein turnover and TGF-alpha, bFGF, and EGF receptor expression in humans.
abstract: In order to investigate whether chronic duodenal ulcer disease is a consequence of disturbed mucosal turnover and growth factor expression, we studied 16 patients with duodenal ulcers before, during, and after endoscopic healing with lansoprazole or sucralfate. Before treatment, gastric fundal and antral mucosal protein turnover rates were higher in patients than controls, without parallel increases in growth factors. Both forms of therapy produced similar changes, with overall increases in duodenal mucosal turnover and transforming growth factor-alpha (TGF-alpha) and epidermal growth factor receptor (EGF-r) levels. Measurements after healing showed persistent elevations of mucosal turnover in the antrum and duodenum and depressions of basic fibroblast growth factor (bFGF) in gastric fundal and duodenal mucosa. We conclude that mucosal turnover is abnormally high in patients with chronic duodenal ulcer disease and is not easily explained by growth factor changes. The failure of lansoprazole and sucralfate to normalize rates, despite endoscopic healing, may explain the high ulcer relapse rates in non-HP-eradicated patients.
authors.affiliation: Gastro-Intestinal Clinic, Groote Schuur Hospital and Department of Medicine, University of Cape Town, South Africa.
authors.forename: T
authors.initials: T
authors.lastname: Zhang
authors.forename: S J
authors.initials: SJ
authors.lastname: O'Keefe
authors.forename: T
authors.initials: T
authors.lastname: Winter
authors.forename: I N
authors.initials: IN
authors.lastname: Marks
authors.forename: J
authors.initials: J
authors.lastname: Ogden
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000328:Adult; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D002908:Chronic Disease; D004381:Duodenal Ulcer / Q000188:drug therapy* / Q000378:metabolism*; D066246:ErbB Receptors / Q000378:metabolism; D005260:Female; D016222:Fibroblast Growth Factor 2; D006801:Humans; D007413:Intestinal Mucosa; D064747:Lansoprazole; D008297:Male; D009853:Omeprazole / Q000031:analogs & derivatives* / Q000627:therapeutic use; D017468:Receptors, Fibroblast Growth Factor / Q000378:metabolism; D018125:Receptors, Transforming Growth Factor beta / Q000378:metabolism; D012008:Recurrence; D013392:Sucralfate / Q000627:therapeutic use*
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D017468:Receptors, Fibroblast Growth Factor; D018125:Receptors, Transforming Growth Factor beta; D064747:Lansoprazole; D016222:Fibroblast Growth Factor 2; D013392:Sucralfate; D066246:ErbB Receptors; D009853:Omeprazole